REVIEW ON OCULAR INSERT DRUG DELIVERY SYSTEM
Abstract
An ocular insert represents an advanced technology in eye disease therapy. Designing and development of an ocular insert is a challenge ever faced by Pharmaceutical researchers or manufacturer. In the ophthalmology; eye drop have ever found to be an easy remedy from the administration point of view. In case of conventional dosage forms the fast precorneal loss of drug has been a major difficulty. To improve ocular drug bioavailability, there are significant guidelines have been directed towards newer drug delivery systems for ophthalmic administration. By means of ocular insert, the researcher has always taken efforts to release the drug at controlled rate to avoid frequent administration of drug. The ocular insert consist of controlled, delayed or sustained release biodegradable implantable components of different material in multiple layers. The inserts can be classified in various classes like Insoluble, soluble or biodegradable as per its solubility. The release of drug from the insert depends upon the diffusion, osmosis, and bioerosion of the drug.
Keyword: Ocular inserts, bioerosion, osmosis, bioerodible implant,
Downloads
Download data is not yet available.
References
1. Katz IM. Shaped ophthalmic inserts for treating dry eyes syndrome. aUS Patent 1982;4:343-787.
2. Cohen, E.M., Grim, W.M., Harwood, R.J., and Mehta, G.N., “Solid state ophthalmic medication, U.S. Patent, 1979; 4:, 179,597.
3. Bawa, R., “Ocular inserts, In: Ophathalmic drug delivery systems, Marcel Dekker, Inc., New York (Mitra.A.K edr), 1993; 58:223.
4. Chien YW.et al, “Ocular drug delivery and delivery systems” In: Novel drug delivery systems. 2 nd ed. New York: Marcel Dekker; 1992.
5. Saettone MF. Solid polymeric inserts/disks as ocular drug delivery systems. In: Edman P, editor. Biopharmaceutics of ocular drug delivery. Boca Raton: CRC Press; 1993. p. 61-79.
6. Khar RK et al, “Targeted and Controlled drug delivery novel carrier systems” 1 st ed. New Delhi; CBS Publishers and Distributors; 2002.
7. Rajput G et al, “A Review on ophthalmic inserts”, International journal of pharma professional research, 2013,4(3): pp-912-920
8. Sowjanya A et al, “Overview of current technologies in ocuserts for the treatment of ophthalmic diseases”, IJRPS, 2012, 3(4), pp-509-516.
9. Tangri et al ,“ Basics of Ocular Drug Delivery Systems ”, International Journal of Research in Pharmaceutical and Biomedical Sciences Vol. 2(4), Oct – Dec, 2011,pp.1541-1552.
10. Sahane NK et al, “Ocular Inserts: A Review”, Drug Invention Today, 2010,2(1):pp- 57-64.
11. Zaffaroni A et al, “Osmotic releasing device having a plurality of release rate patterns”, U.S. Patent: 1977,4, 036, 227.
12. Chien YW. Ocular drug delivery and delivery systems. In: Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 1992. p. 269-70.
13. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Del Rev 1995; 16:95-106.
14. Brahmankar D.M et al, “Biopharmaceutics and Pharmacokinetics a treatise, Vallabh Prakashan, 2010,pp-470-475.
15. Rathore K.S et al, “Review on ocular inserts”, International Journal of Pharm Tech Research volume 1, pp.164-169.
16. Bloomfield et al,“ Soluble gentamacin ophthalmic inserts as a delivery system”, J.Pharm. Sci., 1987, 76: 583
17. Mitra, A.K. et al, “Ophthalamic drug delivery, In: Drug Delivery Devices, Marcel Dekker, Inc, New York,1998: 455.
18. Thakur Richa et al, ‟ Promising Inplication of Ocuserts in Ocular Disease”, Journal of drug delivery & Therapeutics,2012,2(2),pp-18-25
19. Thakur RR et al,“ Modern Delivery Systems for Ocular Drug Formulations:A Comparative Overview W.R.T Conventional Dosage ”, International Journal of Research in Pharmaceutical and Biomedical Sciences, 2011, 2 (1), pp-8-18.
20. Grass GM, Cobby J, Makoid MC. Ocular delivery of Pilocarpine from erodible matrices. J Pharm Sci 1984;73:618-21.
21. Punch PI, Slatter DH, Costa ND, Edwards ME. Investigation of gelatin asa possible biodegradable matrix for Sustained delivery of gentamicin to the bovine eye. J Vet Pharmacol Ther 1985;8:335-8.
22. Attia MA, Kassem MA, Safwat SM. In vivo per formance of 3-Hdexamethasone ophthalmic film delivery system in the Rabbit eye. Int J Pharm 1988; 47:21.
23. Menqi S.A. et al, “Controlled and Novel drug delivery systems, CBS Publishers, New Delhi,2004,pp-82-96.
24. Brahmankar D.M. et al, “Biopharmaceutics and Pharmacokinetics a treatise, Vallabh Prakashan, 2010, pp-470-475.
25. Hajare A., Mali S., Salunke S. (2014). A rational approach to ocular drug delivery system: a overview. WJPR 3(2); 3324-3348.
26. Nayak B.S., Patnaik S.C., Sethy S., Ellaiah P., Sarangi B. K. (2015). Formulation design and in vitro-in vivo evaluation of moxifloxacin ophthalmic insert. American J. of Phytomed. And Clinical Therap., 4; 302-312.
27. Venkata Ratnam G et al, ‟ Ocular Drug Delivery: an update review”, IJPBS Volume 1, Oct-Dec, 2011, pp.437-446.
28. Lee VH, Robinson JF. Review: Topical ocular drug delivery; recent developments and future challenges. J Ocul Pharmacol 1976; 2:67.
29. Alvarez-Lorenzo C, Hiratani H. Soft contact lenses capable of sustained delivery of timolol. J Pharm Sci 2002; 91: 2182-92.
30. Korsmeyer RW, Peppas NA. Macromolecular and modeling aspects of swelling-controlled systems. In: Roseman TJ, Mansdorf SZ editor. Controlled Release Delivery Systems. New York: Marcel Dekker; 1983.
31. Darougar S. Patent literature review of ocular inserts. US Patent 1999;6: 264-971.
32. Shukr M. (2013). Formulation, in vitro and in vivo evaluation of lidocaine HCl ocular inserts for topical ocular anesthesia. Arch. of pharm. research, 2; 23-30.
33. Khurana G., Arora S., Pawar P. (2012) Ocular insert for sustained delivery of gatifloxacin sesquihydrate: preparation and evaluations. Int. J. of pharm. Invest. 2(2): 70–77.
34. Dave V. (2013). Formulation and evaluation of controlled delivery of aceclofenac through ocular insert. Turk J Pharm Sci., 10(2); 205-220.
35. Dave V., Sharma S., Paliwal S. (2013). Design and evaluation of esmolol hydrochloride ocular inserts with special reference to glaucoma treatment. JPI, 4; 89–99.
2. Cohen, E.M., Grim, W.M., Harwood, R.J., and Mehta, G.N., “Solid state ophthalmic medication, U.S. Patent, 1979; 4:, 179,597.
3. Bawa, R., “Ocular inserts, In: Ophathalmic drug delivery systems, Marcel Dekker, Inc., New York (Mitra.A.K edr), 1993; 58:223.
4. Chien YW.et al, “Ocular drug delivery and delivery systems” In: Novel drug delivery systems. 2 nd ed. New York: Marcel Dekker; 1992.
5. Saettone MF. Solid polymeric inserts/disks as ocular drug delivery systems. In: Edman P, editor. Biopharmaceutics of ocular drug delivery. Boca Raton: CRC Press; 1993. p. 61-79.
6. Khar RK et al, “Targeted and Controlled drug delivery novel carrier systems” 1 st ed. New Delhi; CBS Publishers and Distributors; 2002.
7. Rajput G et al, “A Review on ophthalmic inserts”, International journal of pharma professional research, 2013,4(3): pp-912-920
8. Sowjanya A et al, “Overview of current technologies in ocuserts for the treatment of ophthalmic diseases”, IJRPS, 2012, 3(4), pp-509-516.
9. Tangri et al ,“ Basics of Ocular Drug Delivery Systems ”, International Journal of Research in Pharmaceutical and Biomedical Sciences Vol. 2(4), Oct – Dec, 2011,pp.1541-1552.
10. Sahane NK et al, “Ocular Inserts: A Review”, Drug Invention Today, 2010,2(1):pp- 57-64.
11. Zaffaroni A et al, “Osmotic releasing device having a plurality of release rate patterns”, U.S. Patent: 1977,4, 036, 227.
12. Chien YW. Ocular drug delivery and delivery systems. In: Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 1992. p. 269-70.
13. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Del Rev 1995; 16:95-106.
14. Brahmankar D.M et al, “Biopharmaceutics and Pharmacokinetics a treatise, Vallabh Prakashan, 2010,pp-470-475.
15. Rathore K.S et al, “Review on ocular inserts”, International Journal of Pharm Tech Research volume 1, pp.164-169.
16. Bloomfield et al,“ Soluble gentamacin ophthalmic inserts as a delivery system”, J.Pharm. Sci., 1987, 76: 583
17. Mitra, A.K. et al, “Ophthalamic drug delivery, In: Drug Delivery Devices, Marcel Dekker, Inc, New York,1998: 455.
18. Thakur Richa et al, ‟ Promising Inplication of Ocuserts in Ocular Disease”, Journal of drug delivery & Therapeutics,2012,2(2),pp-18-25
19. Thakur RR et al,“ Modern Delivery Systems for Ocular Drug Formulations:A Comparative Overview W.R.T Conventional Dosage ”, International Journal of Research in Pharmaceutical and Biomedical Sciences, 2011, 2 (1), pp-8-18.
20. Grass GM, Cobby J, Makoid MC. Ocular delivery of Pilocarpine from erodible matrices. J Pharm Sci 1984;73:618-21.
21. Punch PI, Slatter DH, Costa ND, Edwards ME. Investigation of gelatin asa possible biodegradable matrix for Sustained delivery of gentamicin to the bovine eye. J Vet Pharmacol Ther 1985;8:335-8.
22. Attia MA, Kassem MA, Safwat SM. In vivo per formance of 3-Hdexamethasone ophthalmic film delivery system in the Rabbit eye. Int J Pharm 1988; 47:21.
23. Menqi S.A. et al, “Controlled and Novel drug delivery systems, CBS Publishers, New Delhi,2004,pp-82-96.
24. Brahmankar D.M. et al, “Biopharmaceutics and Pharmacokinetics a treatise, Vallabh Prakashan, 2010, pp-470-475.
25. Hajare A., Mali S., Salunke S. (2014). A rational approach to ocular drug delivery system: a overview. WJPR 3(2); 3324-3348.
26. Nayak B.S., Patnaik S.C., Sethy S., Ellaiah P., Sarangi B. K. (2015). Formulation design and in vitro-in vivo evaluation of moxifloxacin ophthalmic insert. American J. of Phytomed. And Clinical Therap., 4; 302-312.
27. Venkata Ratnam G et al, ‟ Ocular Drug Delivery: an update review”, IJPBS Volume 1, Oct-Dec, 2011, pp.437-446.
28. Lee VH, Robinson JF. Review: Topical ocular drug delivery; recent developments and future challenges. J Ocul Pharmacol 1976; 2:67.
29. Alvarez-Lorenzo C, Hiratani H. Soft contact lenses capable of sustained delivery of timolol. J Pharm Sci 2002; 91: 2182-92.
30. Korsmeyer RW, Peppas NA. Macromolecular and modeling aspects of swelling-controlled systems. In: Roseman TJ, Mansdorf SZ editor. Controlled Release Delivery Systems. New York: Marcel Dekker; 1983.
31. Darougar S. Patent literature review of ocular inserts. US Patent 1999;6: 264-971.
32. Shukr M. (2013). Formulation, in vitro and in vivo evaluation of lidocaine HCl ocular inserts for topical ocular anesthesia. Arch. of pharm. research, 2; 23-30.
33. Khurana G., Arora S., Pawar P. (2012) Ocular insert for sustained delivery of gatifloxacin sesquihydrate: preparation and evaluations. Int. J. of pharm. Invest. 2(2): 70–77.
34. Dave V. (2013). Formulation and evaluation of controlled delivery of aceclofenac through ocular insert. Turk J Pharm Sci., 10(2); 205-220.
35. Dave V., Sharma S., Paliwal S. (2013). Design and evaluation of esmolol hydrochloride ocular inserts with special reference to glaucoma treatment. JPI, 4; 89–99.
Statistics
462 Views | 1223 Downloads
How to Cite
1.
Devhadrao N, Siddhaia M. REVIEW ON OCULAR INSERT DRUG DELIVERY SYSTEM. JDDT [Internet]. 15Oct.2018 [cited 17Oct.2021];8(5-s):115-21. Available from: http://jddtonline.info/index.php/jddt/article/view/1991
Issue
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.